CHD vs CL

Key Takeaways

• CHD has outperformed the broader market year-to-date, driven by resilient brand momentum and a focus on faster-growing personal care categories.
• CL offers greater scale, global diversification, and a higher dividend yield, but faces softer growth in its North America segment.
• Both companies are defensive consumer staples, yet their growth profiles differ meaningfully: CHD skews toward U.S. household and personal care, while CL derives most of its revenue from international markets.
• Valuation is elevated for both stocks, with forward price-to-earnings multiples in the low-to-mid 20s, leaving limited room for multiple expansion.
• Relative performance in recent weeks has favored CHD, although CL's brand-restructuring efforts could act as a near-term catalyst.

Introduction

Church & Dwight Co., Inc. (CHD) and Colgate-Palmolive Company (CL) are two of the most recognizable names in household and personal care. Both operate in the defensive consumer staples sector, selling everyday products that generate stable, recurring demand regardless of economic conditions. This stock comparison is particularly relevant for investors weighing quality consumer franchises with different growth engines, geographic exposures, and capital-return profiles. Income-focused investors may favor CL's higher yield, while growth-oriented investors may be drawn to CHD's faster organic expansion. Understanding their relative performance and market positioning can help traders and long-term investors assess which name aligns better with current market conditions.

CHD Overview and Recent Performance

Church & Dwight is a diversified consumer products company best known for its ARM & HAMMER brand, alongside a portfolio that includes THERABREATH oral care, HERO skincare, TROJAN, and the recently acquired TOUCHLAND hand sanitizer brand. The company generates roughly $6.2 billion in annual revenue and has built a reputation for reliable organic growth through innovation and targeted acquisitions.

In recent weeks, CHD shares have traded near the $94 level, with a 52-week range between roughly $81 and $106. The stock's beta of approximately 0.47 reflects its defensive, low-volatility character. Year-to-date, CHD has meaningfully outperformed the S&P 500, supported by better-than-expected earnings and resilient consumer demand. Management's 2026 guidance calls for adjusted earnings per share growth of about 5% to 8% and volume-driven organic sales growth of approximately 3% to 4%. Key drivers include expansion of ARM & HAMMER, growth of the THERABREATH oral care line, and international growth. Headwinds include elevated marketing investment, persistent inflation, and tariff-related cost pressures, as well as the prior exit from the vitamins business.

CL Overview and Recent Performance

Colgate-Palmolive is a global leader in oral care, holding roughly 41% of the worldwide toothpaste market and about 33% of the manual toothbrush market. Its portfolio spans oral care, personal care, home care, and the Hill's Pet Nutrition business. With annual revenue exceeding $20 billion, CL is significantly larger than CHD and generates a substantial majority of its sales outside the United States.

In recent weeks, CL shares have traded near the $84 level, within a 52-week range of approximately $74 to $99. The company has delivered consistent organic sales growth, most recently posting mid-single-digit gains in several quarters, driven by strength in emerging markets such as India, Brazil, and Mexico. However, North America has been its weakest region, weighed down by softer volumes and competitive pressure. CL has also announced plans to explore the sale of certain mass-market personal care brands, including Softsoap, Irish Spring, and Speed Stick, signaling a portfolio simplification strategy. As a Dividend King, CL has raised its dividend for more than six decades and currently offers a yield near 2.5%.

Trending AI Robots

For traders seeking a data-driven edge in this type of stock comparison, Tickeron's Trending AI Robots page offers a curated view of its strongest-performing automated strategies. Tickeron hosts hundreds of AI Trading Bots that collectively trade thousands of different tickers, but only those best suited to current market conditions earn a place in this featured section. These bots vary widely in trading style, strategy, timeframe, performance history, and the specific sets of tickers they follow, allowing users to match a bot's approach to their own risk tolerance and objectives. Exploring the Trending AI Robots page can help investors see how systematic, AI-driven analysis currently ranks names like CHD and CL relative to the broader market.

Head-to-Head Comparison

Although both companies operate in consumer staples, their business models and growth drivers diverge in important ways. CHD is a domestic-focused growth story built on innovation and bolt-on acquisitions, with a leaner portfolio concentrated in high-margin household and personal care niches. Its recent momentum reflects successful new product launches and steady gross-margin expansion. CL, by contrast, is a global scale player whose results hinge more on emerging-market demand, currency movements, and category leadership in oral care.

From a risk standpoint, CHD carries more exposure to U.S. consumer spending and rising marketing costs, while CL faces currency volatility, geopolitical risk across its many markets, and a challenged North American business. On valuation, both trade at premium multiples: CHD's forward price-to-earnings ratio sits in the low-to-mid 20s, and CL's is comparable, leaving little cushion if growth disappoints. In terms of income, CL's higher dividend yield and lengthy dividend-growth history give it an edge for income-oriented investors, whereas CHD's faster organic growth and stronger recent relative performance may appeal to those prioritizing momentum.

Tickeron AI Verdict

Based on observable trend consistency, relative momentum, and near-term catalysts, Tickeron's AI framework would likely lean toward CHD in the current environment. CHD has demonstrated steadier upward price momentum and stronger year-to-date relative performance, backed by consistent organic growth and margin expansion. CL's global scale and dependable dividend remain compelling, but softer North American volumes and portfolio restructuring introduce greater near-term uncertainty. This probabilistic view does not constitute a prediction, and both stocks carry meaningful valuation risk at current levels.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations